Regeneron stock gets FDA approval for Livsayis in myasthenia gravis
Published on 11/19/2026 at 14:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSA new rare-disease approval
- The FDA approved Livsayis for adults with antibody-positive generalized myasthenia gravis.
- Regeneron assumed responsibility for the therapy's development, manufacturing and commercialization in 2024.
- The treatment is an RNAi medicine administered under the skin four times a year.
On Thursday, November 19, 2026, Alnylam Pharmaceuticals announced that the U.S. Food and Drug Administration had approved Livsayis (cemdisiran), an RNAi therapy developed and commercialized by Regeneron, for adults with generalized myasthenia gravis who are positive for anti-acetylcholine receptor antibodies. The approval creates a new regulatory milestone for Regeneron's rare-disease portfolio.
Livsayis is administered subcutaneously four times a year. The therapy is designed to reduce production of complement component 5 by silencing the messenger RNA that encodes the protein. Complement activation contributes to damage at the neuromuscular junction in antibody-positive generalized myasthenia gravis, a chronic autoimmune disease that can cause severe muscle weakness.
Regeneron takes commercial responsibility
Alnylam discovered Livsayis and advanced it into Phase 2 development before the molecule became part of an RNAi collaboration with Regeneron. Regeneron assumed sole responsibility for development, manufacturing and commercialization in 2024 and subsequently advanced the therapy through late-stage development.
The approval also activates an economic term in the companies' agreement. Alnylam said it will receive a 25 million US dollar payment from Regeneron for the regulatory milestone and may receive tiered royalties in the double-digit range, reaching up to 15 percent of global net sales. The payment is an obligation to Alnylam and is not presented as Regeneron's revenue.
Commercial opportunity and execution
For Regeneron, the decision expands its presence in a rare autoimmune disorder and gives the company a product that can be administered quarterly. The commercial opportunity will depend on physician adoption, patient access, reimbursement and the company's ability to establish the therapy in a market that includes existing approaches to complement inhibition.
The approval also illustrates the strategic value of Regeneron's partnership model. Regeneron brings late-stage development, manufacturing and commercialization responsibility to a molecule originating from Alnylam's RNAi platform. Alnylam described Livsayis as the first RNAi therapeutic approved for generalized myasthenia gravis.
Regeneron stock traded at 860.00 euros on Lang & Schwarz at 14:30 CET on Thursday, November 19, 2026. The quote provides the market level for the publication time; the regulatory announcement and the commercial terms remain the central investor considerations.
Regeneron Pharmaceuticals at a glance
- Company: Regeneron Pharmaceuticals, Inc.
- ISIN: US75886F1075
- Product: Livsayis (cemdisiran)
- Indication: Antibody-positive generalized myasthenia gravis in adults
- Lang & Schwarz quote: 860.00 euros at 14:30 CET on November 19, 2026
Investors will now focus on the launch and uptake of Livsayis, the pace of reimbursement and the contribution of the therapy to Regeneron's rare-disease business. The FDA decision is a completed regulatory action; future sales will depend on execution after approval.
The broader U.S. biotechnology market can be followed through the S&P 500.
More news and analyses on Regeneron stock.
Source: Alnylam Pharmaceuticals.
